Maplight Therapeutics insider plans 22,082-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Maplight Therapeutics, Inc. has a filing by James Lillie indicating a proposed sale of up to 22,082 shares of common stock through Jefferies LLC, with an aggregate market value of $287,507.64. The shares relate to vested RSUs dated July 18, 2025, and are listed for NASDAQ trading on or after August 3, 2026.
The filing also lists prior sales of Maplight common stock by James Lillie over the past three months, including transactions such as 24,811 shares sold for $713,661.87 on May 6, 2026, and several smaller trades with specified share counts and dollar amounts.
Key Figures
Key Terms
Vested RSU financial
Securities To Be Sold financial
Securities Sold During The Past 3 Months financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Maplight Therapeutics (MPLT) disclose in this Form 144 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.